Haemonetics (STU:HAZ) Cyclically Adjusted PB Ratio: (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HAZ Haemonetics Corp STU:HAZ
30 GF Score
Price €72.00
GF Value €73.69
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Haemonetics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Haemonetics  (STU:HAZ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Haemonetics Cyclically Adjusted PB Ratio Related Terms


Haemonetics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Haemonetics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics Cyclically Adjusted PB Ratio Chart

Haemonetics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.79 4.84 4.90 3.64 3.16

Haemonetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.25 2.77 4.57 3.16 0.00

STU:HAZ vs IRTC, ITGR, LIVN: Cyclically Adjusted PB Ratio Comparison

For the Medical Devices subindustry, Haemonetics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Haemonetics's Cyclically Adjusted PB Ratio falls into.


STU:HAZ
30GF Score
Haemonetics Corp STU:HAZ
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haemonetics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Haemonetics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Haemonetics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=15.898/333.9520*333.9520
=15.898

Current CPI (Jun. 2026) = 333.9520.

Haemonetics Quarterly Data

Book Value per Share CPI Adj_Book
201609 12.952 241.428 17.916
201612 14.101 241.432 19.505
201703 13.234 243.801 18.128
201706 13.095 244.955 17.853
201709 12.757 246.819 17.261
201712 13.023 246.524 17.642
201803 11.658 249.554 15.601
201806 11.173 251.989 14.807
201809 11.643 252.439 15.403
201812 11.086 251.233 14.736
201903 11.585 254.202 15.220
201906 10.301 256.143 13.430
201909 10.474 256.759 13.623
201912 10.262 256.974 13.336
202003 10.558 258.115 13.660
202006 10.665 257.797 13.816
202009 11.184 260.280 14.350
202012 11.633 260.474 14.915
202103 12.082 264.877 15.233
202106 11.016 271.696 13.540
202109 11.629 274.310 14.157
202112 12.654 278.802 15.157
202203 13.310 287.504 15.460
202206 14.203 296.311 16.007
202209 14.550 296.808 16.371
202212 14.522 296.797 16.340
202303 15.144 301.836 16.755
202306 15.739 305.109 17.227
202309 16.503 307.789 17.906
202312 17.033 306.746 18.544
202403 17.389 312.332 18.593
202406 16.443 314.175 17.478
202409 15.717 315.301 16.647
202412 17.240 315.605 18.242
202503 15.747 319.799 16.444
202506 15.884 322.561 16.445
202509 15.477 324.800 15.913
202512 16.622 324.054 17.130
202603 15.221 330.213 15.393
202606 15.898 333.952 15.898

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued. The current stock price of €72.00 is trading 2.3% below its estimated GF Value™ of €73.69. GuruFocus considers Haemonetics to be Fairly Valued.

Key valuation signals for STU:HAZ:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €73.69 vs. price of €72.00 (2.3% below fair value)
  • GF Score™: 30/100 with 6 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
30GF Score

Get the complete analysis for STU:HAZ

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€72.00
Price
€73.69
GF Value